Sphenopalatine Ganglion Blocks: SPG Blocks are also commonly called Pterygopalatine Ganglion Blocks

These are an amzing number of medical claims found in patents for using Sphenopalatine Ganglion Stimulators to treat many medical conditions. In my experience patients can get these same results with self administered SPG Block.

It is important to understand that the Sphenopalatine Ganglion is actually a part of the brain located outside of the calvarium which houses most of the brain, which is why it is easily accessible. It contains connections to both the Sympathetic and Parasympathetic nervous systems that are controlled (and control) the hypothalamus. The hypothalamus is supercharged with connections in the Reticular Activating System and both of these are parts of the Limbic System or Emotional System but also motivation, emotion, learning, and memory. These also control pleasure and pain.
The hypothalamus maintains our bodies homeostasis and in turn drives the pituitary gland and the adrenal glands. The Sphenopalatine Ganglion is our secret back door to these powerful systems and this explains the enormous list of medical claims found in this and other patents.

The Spenopalatine Ganglion Block can have amazing results as you can see from these videos.

Learn more about SPG Blocks at https://www.SphenopalatineGanglionBlocks.com


While it is effective for treating TMJ, Fibromyalgia, Migraines and Cluster headaches it has expanded uses as well.
The following information is from a Patent Application that is a public record.
A method for suppressing or preventing pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, urinary bladder disorders, abnormal metabolic states, disorders of the muscular system, and/or neuropsychiatric disorders in a patient,
(i) pain resulting from one or more medical conditions comprising:
migraine headaches, including migraine headaches with aura, migraine headaches without aura, menstrual migraines, migraine variants, atypical migraines, complicated migraines, hemiplegic migraines, transformed migraines, and chronic daily migraines; episodic tension headaches; chronic tension headaches; analgesic rebound headaches; episodic cluster headaches; chronic cluster headaches; cluster variants; chronic paroxysmal hemicrania; hemicrania continua; post-traumatic headache; post-traumatic neck pain; post-herpetic neuralgia involving the head or face; pain from spine fracture secondary to osteoporosis; arthritis pain in the spine, headache related to cerebrovascular disease and stroke; headache due to vascular disorder; reflex sympathetic dystrophy, cervicalgia; glossodynia, carotidynia; cricoidynia; otalgia due to middle ear lesion; gastric pain; sciatica; maxillary neuralgia; laryngeal pain, myalgia of neck muscles; trigeminal neuralgia; post-lumbar puncture headache; low cerebro-spinal fluid pressure headache; temporomandibular joint disorder; atypical facial pain; ciliary neuralgia; paratrigeminal neuralgia; petrosal neuralgia; Eagle’s syndrome; idiopathic intracranial hypertension; orofacial pain; myofascial pain syndrome involving the head, neck, and shoulder; chronic migraneous neuralgia, cervical headache; paratrigeminal paralysis; sphenopalatine ganglion neuralgia; carotidynia; Vidian neuralgia; and causalgia; (ii) movement disorders resulting from one or more medical conditions comprising: Parkinson’s disease; cerebropalsy; dystonia; essential tremor; and hemifacial spasms; (iii) epilepsy, including generalized and partial epilepsy; (iv) cerebrovascular diseases resulting from one or more medical conditions comprising: aneurysms, strokes, and cerebral hemorrhage; (v) autoimmune diseases resulting from one or more medical conditions comprising multiple sclerosis; (vi) sleep disorders resulting from one or more medical conditions comprising sleep apnea and parasomnias; (vii) autonomic disorders resulting from one or more medical conditions comprising: gastrointestinal disorders, including but not limited to gastrointestinal motility disorders, nausea, vomiting, diarrhea, chronic hiccups, gastroesphageal reflux disease, and hypersecretion of gastric acid; autonomic insufficiency; excessive epiphoresis; excessive rhinorrhea; and cardiovascular disorders including but not limited to cardiac dysrythmias and arrythmias, hypertension, and carotid sinus disease; (viii) urinary bladder disorders resulting from one or more medical conditions comprising spastic or flaccid bladder; (ix) abnormal metabolic states resulting from one or more medical conditions comprising hyperthyroidism or hypothyroidism (x) disorders of the muscular system resulting from one or more medical conditions comprising muscular dystrophy and spasms of the upper respiratory tract and face; and (xi) neuropsychiatric disorders resulting from one or more medical conditions comprising: depression, schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
Patent name and link to entire patent: Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions US 6526318 B1 https://www.google.ch/patents/US6526318
SPGBlocksuppressingpain, #SPGBlockPreventingPain,

SPGBlockMigraineheadachewithaura, #SPGBlockatypicalmigraines, #SPGBlockeaglessyndrome, #spgblockschizophrenia, #SPGBlockobsessivecompulsivedisorder, #SPGBlockBipolardisorder, #SPGBlockneuropsychiatricdisorder, #SPGBlockcerebrovasculardiseases, #SPGBlocklowcerebro-spinalfluidpressureheadache, #SPGBlockmovementdisorders, #SPGBlocksleepdisorders, SPGBlockurinarydisorders, #SPGblocksciatica, #SPGBlocktransformedmigraine, #SPGBlockcervicalgia, #SPGBlockchronicparoxysmalhemicrania, #spgblockposttraumaticheadache, #SPGBlockpost-herpetic neuralgia